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Summary
Systolic heart failure is frequently accompanied by a relevant functional mitral valve regurgitation (FMR) which develops as a direct sequela
of the ongoing left ventricular remodelling. The severity of mitral regurgitation is further aggravated by progressive left ventricular
enlargement causing leaflet tethering and reduced systolic leaflet movement. The prognosis of such patients is obviously limited by an
underlying left ventricular disease, and the correction of secondary FMR has been previously suggested as predominantly ‘cosmetic’
surgery in the setting of ongoing cardiomyopathy. Inferior results of an isolated annuloplasty in type IIIb FMR supported the philosophy of
malignant course of progressive cardiomyopathy and resulted in increasingly restricted indications for mitral valve surgery for FMR in the
guidelines. The lack of a standardized pathophysiological approach to correct type IIIb FMR led to the development of valve replacement
strategy and edge-to-edge catheter-based mitral valve procedures, which became the most frequent procedures in the FMR setting in
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standardized subannular repair to address the pathophysiological background of type IIIb FMR. The perioperative results have been sig-
nificantly improved, and there is a growing evidence of improved long-term stability of subannular repair procedures as compared to iso-
lated annuloplasty. This review article aims to present the current state-of-the-art of the modern mitral valve surgery in FMR and provides
suggestions for future trials analysing the potential advantages in these patients.
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INTRODUCTION
The progression of chronic heart failure is associated with on-
going left ventricular (LV) remodelling and subsequent changes
in the geometry of the mitral valve apparatus. While LV deform-
ation and enlargement progress, a complex remodelling process
of the whole ‘ventriculo-mitral unit’ occurs and results in geomet-
rical distortion of the subvalvular mitral apparatus [1]. Because of
the ventricular origin of resulting mitral regurgitation (MR), the
definition of functional or secondary mitral regurgitation (FMR)
has been adopted to differentiate this entity from the degenera-
tive (i.e. primary) mitral valve disease primarily caused by the
structural changes of mitral valve leaflets. Despite the
univocal evidence of underlying left ventricular disease in FMR
patients, the standard surgical treatment of FMR for decades
has been an isolated annuloplasty using various ring designs,
all of them aiming to reduce the anteroposterior (i.e. so-called
septolateral) diameter of the mitral valve annulus. Given the well-
documented long-term ineffectiveness of an isolated annulo-
plasty in the advanced FMR and MR recurrence rates up to 60%
at 2 years postoperatively [2], the focus has shifted towards the
mitral valve replacement strategy and towards a worldwide
boom in catheter-based percutaneous edge-to-edge therapy [3].
The basic tenor of irreparable end-stage left ventricular disease
has been often used to justify the failure of annuloplasty concept
in type IIIb FMR and has resulted in a stepwise downgrading of
the level of evidence for mitral valve repair in secondary MR in
the recent updates of consensus guidelines [4].
Modern mitral valve surgery for FMR combines the benefits of
well-established full-endoscopic minimally invasive surgical ap-
proach with the standardized subannular repair to address the
distorted geometry of the subvalvular mitral valve apparatus.
While routinely using these techniques, the evidence of improved
echocardiographic and functional outcomes in FMR treatment is
evolving and is summarized in the present review article. The
clinical adoption is still limited due to unproven reproducibility
of subannular techniques in well-designed, prospective multi-
centre trials and lack of data regarding prognostic benefits in the
FMR treatment.
FUNCTIONAL MITRAL REGURGITATION: A
HOMOGENEOUS ENTITY?
Carpentier’s classification describes MR in relation to the mitral
valve leaflet motion: type I, normal leaflet motion; type II, leaflet
prolapse; type IIIa, restricted leaflet motion in the diastole; and
type IIIb, restricted leaflet motion in the systole [5]. According to
this classification, 2 distinct pathophysiological entities of FMR
patients with the structurally normal mitral valve can be classi-
fied: (i) FMR patients presenting with predominant mitral annular
dilatation (i.e. type I MR lesion) (Fig. 1A and B) versus (ii) FMR
patients with regurgitation predominantly caused by LV remodel-
ling, papillary muscle displacement and tethering of mitral
leaflets (i.e. type IIIb MR lesion) (Fig. 1C and D). The synonyms
used by interventional cardiologists refer to ‘atrial type’ [6] and
‘ventricular type’ of FMR, which intuitively indicate major differ-
ences in the pathogenesis of these 2 diseases. Type I FMR is com-
mon in patients with relevant left atrial dilatation (e.g. those
presenting with long-standing permanent atrial fibrillation),
which consecutively leads to mitral annular dilatation and central
coaptation defect of mitral leaflets. Left ventricular geometry and
systolic LV function are preserved, and there is no relevant systol-
ic tethering of mitral leaflets [6]. As opposed to this ‘atrial-type’
FMR, type IIIb FMR results from a geometric LV remodelling (i.e.
of ischaemic or non-ischaemic origin) and distortion of the sub-
annular mitral apparatus and is associated with a relevant LV dys-
function and systolic tethering of mitral leaflets [7]. It is intuitive
that these 2 FMR entities should differ not only in terms of their
pathophysiological background but also, even more importantly,
in their surgical treatment strategy and finally in their long-term
prognosis. Therefore, a word of caution is warranted when analy-
sing published data on surgical or catheter-based treatment of
‘universal’ FMR cohorts, as they may potentially consist of various
combinations of type I and type IIIb FMR subgroups.
PATHOPHYSIOLOGICAL BACKGROUND OF
FUNCTIONAL MITRAL REGURGITATION: WHAT
DOES IT MEAN FOR THE TREATMENT STRATEGY?
Although the definition of FMR generally implies the presence of
structurally normal mitral valve leaflets, the treatment strategy for
secondary MR depends on the specific pathophysiological mech-
anism and may, therefore, be different in type I versus type IIIb
lesions.
The development of type I ‘atrial’ FMR correlates with the pro-
gressively increasing left atrial volume (e.g. persistent atrial fibril-
lation patients), which causes an incremental dilatation of
atrioventricular continuity and subsequently leads to a central
leaflet coaptation defect and central regurgitation jet [7]. Given
the fact that LV geometry is sufficiently preserved in these
patients and mitral leaflets move normally to the annular level
during the systole, the surgical or interventional treatment strat-
egy aims to simply reduce mitral annular diameter (and thereby
mitral valve orifice) to re-establish the competence of mitral
valve [8] (Fig. 2A and B).
Type IIIb ‘ventricular’ FMR, defined as secondary MR with
reduced systolic leaflet motion, is a primary disease of the left
ventricle and results from a complex remodelling process of the
whole ‘ventriculo-mitral unit’ [9]. It is a sequela of geometrical
distortion of the subvalvular mitral apparatus caused by LV dila-
tation and remodelling in dilated or ischaemic cardiomyopathy
[1]. From the pathophysiological point of view, type IIIb FMR
results from the increasing distance between the tips of both
papillary muscles and mitral annular plane due to apicolateral
displacement of the papillary muscles in the progressively enlarg-
ing left ventricle (Fig. 3A) [10]. Quite independent of the primary
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LV disease (i.e. ischaemic or non-ischaemic origin), there is a se-
vere left ventricular remodelling, which leads to restricted move-
ment of mitral leaflets during the systole and coaptation line well
below the mitral annular plane. The severity of restriction in the
systolic leaflet movement can be quantitatively graded by so-
called tenting parameters, which are summarized in Fig. 4.
Keeping this in mind, standard surgical technique of restrictive
annuloplasty which has been used for decades to treat type IIIb
FMR [11] is pathogenetically unable to address the underlying re-
gurgitation mechanism of reduced leaflet movement towards the
mitral annular plane in the systole and, therefore, to reproducibly
restore leaflet coaptation plane (Fig. 3B). One of the basic princi-
ples of Carpentier’s mitral valve repair ‘to restore free leaflet mo-
tion’ [5] is, therefore, not achieved by an isolated annuloplasty in
FMR patients with a predominant type IIIb lesion. Quite the con-
trary, there is emerging evidence from the literature that the re-
duction in septolateral dimension by restrictive annuloplasty in
type IIIb FMR aggravates leaflet tethering and even further
restricts leaflet mobility in the systole [12, 13]. This phenomenon
is explained by the fact that restrictive annuloplasty brings in the
posterior mitral annulus towards aortomitral continuity and
thereby increases the distance to the papillary muscle tips [12].
Consequently, the posterior mitral leaflet becomes completely
straightened, immobilized and is completely excluded from co-
aptation in the systole [12, 13].
In accordance with these pathophysiological findings, clinical
data convincingly indicate that an isolated restrictive annulo-
plasty leads to high reoccurrence rate of FMR after mitral valve
repair [2, 14]. Of note, recent prospective randomized
Cardiothoracic Surgical Trials Network (CTSN) trial by Acker et al.
[2] showed an almost 60% reoccurrence rate of MR >_2 in the
annuloplasty group at 2 years postoperatively. Such dismal
results of an isolated mitral valve (MV) annuloplasty in type IIIb
FMR patients have been often justified by an irreversible course
of end-stage LV disease and shifted the focus towards the MV re-
placement strategy as a more reproducible procedure which
would basically eliminate the risk of recurrent MR. Several pro-
spective cohort studies and meta-analyses were performed to
compare the surgical strategy for isolated annuloplasty versus mi-
tral valve replacement in FMR patients [15, 16]. Although all these
studies demonstrated significantly higher FMR recurrence in the
annuloplasty cohort, most of them revealed an increased peri-
operative mortality rate in the MV replacement group [15, 16].
Even though the randomized trial by Acker et al. [2] found no
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significant differences in 2-year mortality and adverse cardiac
events when comparing isolated annuloplasty versus mitral valve
replacement cohorts in ischaemic MR, the authors of the current
review interpret these results in a different way. On the basis of
the findings from this randomized controlled trial, one may con-
clude that an isolated annuloplasty in type IIIb FMR results in the
dismal postoperative results that are comparable to those of mi-
tral valve replacement (i.e. 42% major adverse cardiac and cere-
bral events (MACCE) rate in the annuloplasty cohort vs 42%
MACCE rate in the MV replacement cohort at 2 years postopera-
tively, P = 0.96) [2]. Interestingly, in a post hoc analysis of afore-
mentioned randomized controlled trial, those patients with
successful annuloplasty (i.e. no MR recurrence at 2-year follow-up)
versus those with recurrence of MR >2 demonstrated an evidence
of significantly improved reverse LV remodelling [i.e. left ventricular
end-systolic volume index (LVESVI) 42.7 ± 26.4 ml/m2 (successful re-
pair) vs 62.6 ± 26.9 ml/m2 (MR >2 after repair), P < 0.0001] [2]. This
finding may indicate the prognostic importance of the long-term
stability of mitral repair in type IIIb FMR patients.
An urgent need for pathophysiological correction in type IIIb
FMR has led to the development of several subannular repair
techniques that aim to correct a distorted subvalvular LV
geometry and thereby to better maintain the long-term stability
of MV repair. Subannular techniques are very heterogeneous;
however, they can be subdivided by their mechanism of action
which points out the anatomical structures addressed by suban-
nular repair. Although several groups focused primarily on the
augmentation procedures of posterior mitral leaflet [17, 18] and
the secondary chordae cutting [19], the majority of subannular
reconstruction techniques focused directly on the repositioning
of the papillary muscle [20–24]. Our recent meta-analysis on sub-
annular reconstruction in type IIIb FMR demonstrated that MV
annuloplasty with simultaneous subannular repair was associated
with a 4-fold reduction in the late reoccurrence of MR >_2 after
mitral valve repair as compared to MV annuloplasty alone [25].
Although ‘papillary muscles techniques’ were the most common-
ly used manoeuvres in the included studies [i.e. 411/743 (55.3%)
patients], our meta-analysis was not powered to analyse the most
appropriate subannular manoeuvre in the type IIIb FMR treat-
ment [25]. In addition, our meta-analysis did not include any
comparative data of mitral valve replacement versus subannular
repair in type IIIb FMR which could be of major interest.
Unfortunately, no prospective cohort studies comparing the out-
come of subannular mitral valve repair techniques versus mitral
Figure 2: The functional result of an isolated annuloplasty in 2 different functional mitral regurgitation (FMR) entities. (A and B) The appropriate result after an isolated
annuloplasty in type I FMR. (C and D) Residual leaflet tethering and mitral regurgitation after an isolated annuloplasty in type IIIb FMR (postoperative echocardiog-
raphy at hospital discharge).
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valve replacement in type IIIb FMR patients have yet been
published.
The main drawback of all subannular manoeuvres is marked
heterogeneity and the lack of standardization and, therefore, lim-
ited reproducibility. We recently introduced a subannular repair
technique, which is intended to be standardized and reproducible,
does not significantly prolong aortic-cross-clamp or cardiopulmon-
ary bypass (CPB) time and could be easily performed via a full-
endoscopic and non-rib-spreading MV repair approach [10].
MINIMALLY INVASIVE VALVE REPAIR FOR
FUNCTIONAL MITRAL REGURGITATION:
WHAT IS THE EVIDENCE?
Minimally invasive mitral valve surgery through a right anterolat-
eral minithoracotomy approach became increasingly a standard
of care in the setting of isolated mitral valve surgery [26]. In par-
ticular, very high mitral valve repair rates and an excellent safety
profile using a minimally invasive approach were achieved in
patients with degenerative mitral valve disease [27, 28]. For ex-
ample, a total of >6000 isolated surgical mitral valve procedures
were performed in Germany in 2016, 50% of which were treated
through a minimally invasive access [29]. Multiple studies world-
wide confirmed the hypothesis that minimally invasive mitral
valve surgery does not increase the surgical risk as compared to
conventional sternotomy [28, 30].
In contrast to degenerative mitral valve disease, surgical data
on the systematic use of minimally invasive techniques in the
FMR setting are very sparse. Only few case series have been
reported by single high-volume and high-expertise institutions
[30, 31]. Even though Penicka et al. [31] reported on 167 type IIIb
FMR patients with left ventricular ejection fraction <45% who
underwent minimally invasive mitral valve repair in a single insti-
tution during a 12-year period, their surgical strategy has been
an isolated annuloplasty in all patients, and no subannular repair
was used. Despite significant long-term mortality in mitral annu-
loplasty subgroup (i.e. 44% all-cause mortality during the median
follow-up of 7 years), the aforementioned study demonstrated a
significant long-term survival benefit in the minimally invasive
surgery cohort as compared to the conservative cohort that
received the best medical treatment [31].
The implementation of additional subannular manoeuvres for
minimally invasive mitral valve repair surgery of FMR has been
reported in small case series only [32, 33]. Santana et al. [33]
reported on 19 consecutive patients with severe FMR who
underwent minimally invasive mitral valve repair using a papillary
muscle sling + annuloplasty technique in a single institution.
Study population included represent a typical patients’ cohort
with a type IIIb FMR and severely reduced left ventricular systolic
function (i.e. mean left ventricular ejection fraction of 23%).
Despite relatively long aortic-cross-clamp and CPB times [i.e. the
median aortic-cross-clamp time 106 (interquartile range, IQR,
76–120) min and median CPB time 163 (IQR 119–170) min],
which were required to place a papillary muscle sling properly
around the base of all the papillary muscles, the authors reported
a very satisfying 30-day outcome (0% mortality) and an excellent
mitral valve competence at 3-month echocardiographic follow-
up [33]. However, the aforementioned report represents a limited
single-centre experience with a very short follow-up, and there-
fore, no definite conclusions can be drawn.
Because type IIIb FMR patients will often require subsequent
cardiac surgical interventions due to progressive heart failure
(e.g. left ventricular assist device (LVAD) implantation, heart
transplantation and coronary artery bypass graft surgery), the
specific focus on minimally invasive mitral valve surgery in these
patients is well considered and may significantly simplify subse-
quent reinterventions. On the other hand, we strongly believe
that subannular manoeuvres should be adopted in the minimally
invasive valve surgery setting and should, therefore, be simple
and reproducible not to significantly increase perioperative risk
in these severely compromised patients with multiple comorbid-
ities. Therefore, we briefly describe in the following sections our
current surgical strategy for minimally invasive mitral valve repair
for type IIIb FMR which includes a standardized subannular re-
construction manoeuvre [10].
Figure 3: (A) Functional impact of left ventricular remodelling on mitral valve geometry in type IIIb functional mitral regurgitation. (B) The principle of pathophysio-
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Nowadays, routine diagnostic workup for minimally invasive
surgery includes a native chest and abdomen computed tomog-
raphy scan to exclude relevant calcifications in the thoracic/ab-
dominal aorta in older patients and those with signs of systemic
atherosclerosis (e.g. coronary artery disease, carotid artery dis-
ease, peripheral artery disease or s/p cerebrovascular accident).
Antegrade arterial perfusion by right axillary artery cannulation
to prevent retrograde flow in the diseased atheromatous aorta
may be potentially advantageous in such patients. Preoperative
echocardiography in FMR patients should specifically differenti-
ate between type I and type IIIb valve lesions and quantify the
tenting parameters (Fig. 4).
A right anterior minithoracotomy and non-rib-spreading
endoscopic approach became the most commonly used tech-
nique for surgical exposure [34]. After surgical exposure of the
mitral valve and intraoperative confirmation of type IIIb mitral
valve lesion, pledgeted 3-0 polytetrafluorethylen (PTFE) sutures
are passed in a U-form fashion through the trunks of both papil-
lary muscles (Fig. 5A). Both PTFE sutures are then advanced be-
hind the posterior mitral valve annulus from the ventricular to
the atrial side in the corresponding segments (Fig. 5B). Mitral
annuloplasty is then performed in the standard fashion using a
complete undersized annuloplasty ring. After the annuloplasty
ring is completely secured by sutures, both PTFE sutures are
passed through the posterior aspect of the annuloplasty ring
(Fig. 5C). In the following step, the left ventricle is pressurized
with a cold saline to induce the maximal possible tenting of mi-
tral leaflets. Stepwise traction is then applied on both PTFE
sutures aiming to bring the anterior leaflet to the level of the
annuloplasty ring. After reaching the appropriate position of the
anterior leaflet, both sutures are tightly secured on the annulo-
plasty ring (Fig. 5D) and thereby fixing the distance between the
papillary muscle tips and mitral annular plane.
The procedural success of subannular reconstruction may
be defined as a nearly complete disappearance of anterior
leaflet tenting (i.e. the coaptation line reaches the level of the
annuloplasty ring), tenting height of <5 mm and no/trivial
residual MR in the intraoperative transoesophageal echocardi-
ography (Fig. 6). The interim analysis of 100 consecutive
patients over a period of 2 years showed that our subannular
manoeuvre can be safely performed and without significant
prolongation of aortic-cross-clamp/CPB times. Over a period of
2 years, this manoeuvre has become the standard surgical
procedure in type IIIb FMR patients at the University Heart
Center Hamburg and is now routinely performed by 5 mitral
valve surgeons.
PROGNOSTIC IMPLICATIONS OF SURGICAL
FUNCTIONAL MITRAL REGURGITATION
TREATMENT: WHAT KIND OF EVIDENCE
DO WE NEED?
The main drawback of surgical and interventional FMR treatment
is the lack of appropriate prognostic evidence that convincingly
demonstrates the benefits of reducing MR on the long-term
prognosis of FMR patients as compared to the guideline-directed
medical therapy [35]. In other words, the key question regarding
FMR treatment—how many survival years and how much quality
of life does the competent mitral valve add for the patients with
a primary ventricular disease—is still unanswered. Also, does the
progression of cardiomyopathy slow down in the setting of surgi-
cally or interventionally corrected MR? The available data for the
treatment of secondary MR are sparse and controversial [35].
Several retrospective studies including 1 propensity score-
matched analysis [36] revealed a significant survival benefit for
Figure 4: Echocardiographic quantification of tenting parameters in the parasternal long-axis view. (A) Coaptation length: distance of overlap between the anterior
mitral leaflet and posterior mitral leaflet during the systole; (B) tenting height: distance between the annular plane and the most atrial margin of the coaptation line;
(C) tenting area: area between the mitral annular plane and mitral leaflets at the end systole; and (D) tenting angles: angle between the mitral annular plane and anter-
ior mitral leaflet angle and between the mitral annular plane and posterior mitral leaflet angle at the end systole. Ao: ascending aorta; LA: left atrium; LV: left
ventricular.
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FMR patients who underwent surgical [31] or catheter-based [36]
treatment of their secondary MR as compared to the medically
treated group. However, all these studies have major methodo-
logical flaws which significantly limit their scientific value: (i)
none of these studies differentiate between type I and type IIIb
FMR and, therefore, represent patient admixture which is difficult
to interpret; (ii) include only a historical control group of medic-
ally treated patients which is not specified (i.e. the percentage of
patients receiving the guideline-directed best medical treatment
remains unknown); (iii) ignore the fact that an isolated annulo-
plasty [31]; and edge-to-edge repair [36] are often not durable in
type IIIb FMR during follow-up, and relevant MR reoccurs in 50–
70% patients. Therefore, these studies do not differentiate
whether progressive heart failure occurs as a sequela of an
underlying myocardial disorder or due to reoccurrence of signifi-
cant MR.
Figure 5: Intraoperative steps of standardized subannular repair for repositioning of both papillary muscles. (A) The placement of PTFE sutures in both papillary
muscles. (B) Advancement of PTFE sutures behind the posterior mitral valve annulus. (C) Annuloplasty and anchoring of polytetrafluorethylen (PTFE) sutures on the
annuloplasty ring. (D) Repositioning of both papillary muscles and fixation of the distance between papillary muscles tips and mitral annuloplasty ring.
Figure 6: Echocardiographic image after repositioning of the papillary muscle to treat type IIIb functional mitral regurgitation (MR). (A and B) The coaptation line of
the anterior mitral leaflet at the level of the annuloplasty ring in the systole, without residual tenting after repositioning of the papillary muscle (red arrow). (C) No re-
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Therefore, we think that we need well-designed prospective
cohort studies which would stratify FMR patients into the type I
and type IIIb cohorts, include a contemporaneous control group
of the best medical treatment and eliminate the confounder of
recurrent MR (e.g. by systematic use of subannular techniques).
We believe that a prospective multicentre REFORM-MR registry
will be the first step to establish the value of standardized suban-
nular repair in type IIIb FMR and to create a solid basis for the
future prospective studies addressing the prognostic benefit of
FMR treatment.
CONCLUSIONS
In summary, FMR cohort is inhomogeneous and consists of 2 dis-
tinct subgroups of patients presenting with a predominantly
‘atrial’ and ‘ventricular’ type of secondary MR. These 2 FMR sub-
groups are different pathophysiological entities and may require
tailored surgical treatment to address the primary mechanism of
FMR. There is emerging evidence that subannular repair might
be beneficial for the long-term outcomes in type IIIb FMR and
should probably become a part of the surgical strategy in these
patients. To achieve pathophysiological MV correction and to re-
lieve the distortion of subannular MV geometry, papillary muscle
repositioning manoeuvres represent the most often used and
most promising surgical technique. Minimally invasive techni-
ques in FMR treatment seem to be feasible and safe, when per-
formed in a standardized fashion and in experienced centres.
Prognostic benefits of FMR elimination in patients with predom-
inant ventricular disease must still be demonstrated in well-
designed prospective studies in the near future.
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